Journal: Clinical Chemistry

Article Title: Immunological measurement of transforming growth factor-beta 1 (TGF-β1) in blood; assay development and comparison

doi: 10.1093/clinchem/43.10.1965

Figure Lengend Snippet: Fig. 1. Calibration curve and im- precision at each calibrator con- centration (median values of n 5 13 runs) for the in-house TGF-b1 immunoassay.

Article Snippet: Commercial immunoassay kits for the comparison determinations of TGF-b1 were purchased: Predicta (Genzyme), Quantikine (R&D Systems, Minneapolis, MN), Amersham (Amersham International), and Promega (Promega).

Techniques:

Journal: Clinical Chemistry

Article Title: Immunological measurement of transforming growth factor-beta 1 (TGF-β1) in blood; assay development and comparison

doi: 10.1093/clinchem/43.10.1965

Figure Lengend Snippet: Fig. 2. Effect of serial sample dilution on the apparent concentrations measured by 4 commer- cially available TGF-b1 immunoassays performed with the activation procedures recommended by the manufacturers.

Article Snippet: Commercial immunoassay kits for the comparison determinations of TGF-b1 were purchased: Predicta (Genzyme), Quantikine (R&D Systems, Minneapolis, MN), Amersham (Amersham International), and Promega (Promega).

Techniques: Activation Assay

Journal: Molecular Cancer Therapeutics

Article Title: Response to trastuzumab, erlotinib, and bevacizumab, alone and in combination, is correlated with the level of human epidermal growth factor receptor-2 expression in human breast cancer cell lines

doi: 10.1158/1535-7163.mct-07-0079

Figure Lengend Snippet: Figure 3. VEGF and VEGFR inhi- bition. A, dose response effects of a VEGFR inhibitor with activity against flt-1 and KDR (Calbiochem) used at 0, 0.1, 0.5, 2.0, 10, and 50 Amol/L. Points, means; bars, SE. B, medium from cell lines cultured for 6 days was tested for VEGF by ELISA. Net VEGF production (pg/mL/cell) was derived using a standard provided in the kit and cell counts. Columns, means; bars, SE. C, correlation between VEGF production and HER2 expression level. Net VEGF production (pg/mL/cell) was plotted against the normalized HER2 expres- sion levels from the immunoblot data (see Fig. 1). Top, the correla- tion coefficient (r) and P value (P). Bars, confidence intervals. D, cell lines were cultured as in (B) with the addition of treatment with 2 Amol/L of erlotinib (black columns ) or 1 Ag/mL of trastuzumab (gray col- umns). Net VEGF production in the drug-treated samples was normal- ized to the net VEGF production in untreated samples. Columns, means; bars, SE.

Article Snippet: VEGFAnalysis by ELISA Endogenous VEGF production and secretion from the cell lines was assayed using the Quantikine human VEGF immunoassay (R&D Systems).

Techniques: Activity Assay, Cell Culture, Enzyme-linked Immunosorbent Assay, Derivative Assay, Expressing, Western Blot

Journal: PLoS ONE

Article Title: Growth Differentiation Factor-15 (GDF-15) Levels Are Associated with Cardiac and Renal Injury in Patients Undergoing Coronary Artery Bypass Grafting with Cardiopulmonary Bypass

doi: 10.1371/journal.pone.0105759

Figure Lengend Snippet: Bar graph illustrating the change in global χ2 value by the addition of post-operative GDF-15 and/or NGAL to post-operative eGFR. All models were significantly associated with AKI (p<0.05). * = p<0.05 vs eGFR model. § = p = 0.06 vs eGFR + NGAL model.

Article Snippet: Plasma GDF-15 concentrations were measured by quantitative sandwich enzyme immunoassay (Human GDF-15, Quantikine, R&D Systems Europe, Lille, France) with a linear range from 200 to 50,000 ng/L.

Techniques: